RxDoctor Payments Data

Kevin Belgrave, MD

Cardiovascular Disease · Torrance, CANPI 1922369743

Payments from drug & device makers

$762in general payments, 2019–2025

Across 42 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$236
  • Johnson & Johnson$156
  • Abiomed$125
  • Biotronik Inc.$40
  • Novartis$35
  • Cardinal Health 200 LLC$34
  • plus $136 from 7 others

What the payments were for

  • Food & beverage$762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$762 in reported general payments places this provider in the 30th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$3,500
Medicare patients
27
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis12$292,310
EliquisApixaban59$86,302
JardianceEmpagliflozin137$72,803
PradaxaDabigatran Etexilate Mesylate237$64,547
EntrestoSacubitril/Valsartan20$29,800
Atorvastatin Calcium478$5,991
Furosemide396$4,708
Amiodarone Hcl143$4,257
Dabigatran EtexilateDabigatran Etexilate Mesylate23$4,165
Metoprolol Tartrate430$4,132
AbrysvoRsv Vacc, Pref A And Pref B/Pf16$2,576
Lisinopril179$2,142
Isosorbide Mononitrate ErIsosorbide Mononitrate73$1,819
Losartan Potassium151$1,582
Bisoprolol Fumarate68$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$35$29,80020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →